GLP-1s & Weight Loss
Cagrilintide
← Back to Library
Human trial protocol FDA safety flag Protocol not independently verified Satiety Metabolic
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 5, 10, 20 mg
Dosing window: Anytime
Receptor / target: Amylin
Properties: Incretin
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 0.25mg once weekly | Initiation phase. |
| Weeks 5-8 | 0.5mg once weekly | Standard dose. |
| Weeks 9-12 | 1.0mg once weekly | Advanced escalation. |
| Weeks 13+ | 2.4mg once weekly | Maximum dose. |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative: Micro-Stacking
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 0.125mg to 0.25mg once weekly | When stacked with Tirzepatide or Semaglutide, kept very low to avoid extreme gastric paralysis. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Weight-loss protocols should not pretend fat loss is only willpower. The logic is appetite signaling, GI tolerance, adherence, protein, resistance training, hydration, and preserving lean mass while the dose changes. Entry context: target (Amylin); route Subcutaneous; timing Anytime. Trial exposure can explain a dose range; it does not validate every goal, stack, or long-term cycle. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. Common diet-myth context matters: rapid vs slow loss is individual, fasting only helps when adherence improves, and protein/training protect lean mass during aggressive deficits.
Independent evidence
Clinical trial regimen(s): Phase 2 dose-finding trial: once-weekly SC cagrilintide 0.3, 0.6, 1.2, 2.4, or 4.5 mg for 26 weeks.
Independent safety notes: FDA states cagrilintide cannot be used in compounding under federal law, is not a component of an FDA-approved drug, and has not been found safe and effective for any condition.
Regulatory status: investigational not FDA approved
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Severe gastroparesis or clinically significant delayed gastric emptying: amylin receptor activation further slows gastric motility; may produce complete gastric stasis.
- Concurrent use with CagriSema (cagrilintide + semaglutide fixed combination): results in double-dosing of cagrilintide.
- High-dose stacking with GLP-1 agonists at full therapeutic doses: combined gastric emptying inhibition can produce extreme gastroparesis and severe caloric restriction; always micro-dose when stacking.
- Type 1 diabetes mellitus without insulin dose adjustment: amylin agonism slows glucose absorption; risk of unpredictable hypoglycemia.
- Hypoglycemia unawareness: gastroparesis caused by amylin agonism delays glucose absorption and may blunt early hypoglycemia recognition.
- Pregnancy: insufficient safety data.
- Breastfeeding: insufficient safety data.
- Known hypersensitivity or anaphylaxis to cagrilintide or any formulation excipient.
- Active bowel obstruction or severe inflammatory bowel disease: GI motility impairment will worsen symptoms.
- Planned general anesthesia or elective surgery: additive gastric emptying delay with any co-administered GLP-1 agent significantly raises pulmonary aspiration risk; follow pre-operative fasting and drug discontinuation protocols.
- End-stage renal disease: safety data limited.
- Pediatric use: safety and efficacy not established.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Nausea: most common adverse effect; driven by amylin receptor activation in the area postrema (the brain's "nausea center"); typically mild to moderate in monotherapy.
- Nausea significantly amplified when stacked with GLP-1 agonists: dual-pathway stimulation of GI motility centers produces additive nausea far exceeding either compound alone.
- Vomiting: more common in stacking protocols than monotherapy.
- Extreme fullness and early satiety: primary pharmacological effect; can become pathological at high combined doses with GLP-1 agonists.
- Inadequate caloric intake: at high stack doses, subjects may be physically unable to consume sufficient calories; requires active monitoring.
- Gastroparesis: clinically significant delayed gastric emptying; risk amplified substantially when combined with any GLP-1 compound.
- Diarrhea.
- Constipation.
- Abdominal pain and cramping.
- Decreased appetite: intended pharmacological effect.
- Hypoglycemia: low risk in monotherapy; elevated risk when stacked with insulin, sulfonylureas, or high-dose GLP-1 agonists; delayed gastric absorption alters glucose uptake kinetics.
- Fatigue and lethargy: frequently secondary to insufficient caloric intake, particularly during aggressive stacking protocols.
- Headache.
- Dizziness.
- Injection site reactions: redness, swelling, itching; well-tolerated in most subjects.
- Administration site conditions: higher rate of injection site adverse events versus semaglutide monotherapy in combination trial data (RR 3.27 in CagriSema vs. semaglutide alone).
- Elevated LDL-C: modestly higher LDL cholesterol observed in combination therapy versus semaglutide alone (MD +0.29 mmol/L); clinical significance uncertain.
- Higher serious adverse event rate in monotherapy versus semaglutide: observed in meta-analysis data (RR 1.83); warrants careful monitoring.
- Pulmonary aspiration risk under general anesthesia: significantly elevated in combination with any GLP-1 agent.
- Rapid weight regain upon discontinuation: expected without lifestyle intervention.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
Sources
- https://the source dataset.com/peptide-codex.php
- https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
- https://pubmed.ncbi.nlm.nih.gov/34798060/
- https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- PubMed search: Cagrilintide
- PubMed trial search: cagrilintide obesity phase 2